Prospective randomized trial of preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma

Prospective randomized trial of preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma - Randomized trial of preoperative TACE for HCC

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005241

Enrollment

Registered

2011-03-20

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

resectable large hepatocelluar carcinoma ( &gt

Interventions

Preoperative TACE Control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: PS(ECOG Performance Status Scale):0-1 Child-Pugh: A or B Major organ function (Bone marrow, Heart, Lung, Liver and Kidney) is good for liver surgery. Written Informed Consent

Exclusion criteria

Exclusion criteria: Recurrence HCC Active double cancer Other preoperative chemothreapy and/or radiation (prior to 4 weeks) Others

Design outcomes

Primary

Measure	Time frame
2-year recurrence free survival rate.	—

Secondary

Measure	Time frame
2-year overall survival rate Ratio of necrosis after TACE Change of serum mRNA level Recurrence site Resection ratio after TACE	—

Countries

Japan

Contacts

Public ContactShogo Kobayashi

Osaka University, Graduate School of Medicine Surgery

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026